[{"data":1,"prerenderedAt":160},["ShallowReactive",2],{"drug-raloxifene":3},{"id":4,"schemaVersion":5,"name":6,"category":9,"class":10,"brands":13,"synonyms":17,"formulations":20,"regimens":35,"contraindications":60,"warnings":70,"renal":78,"monitoring":79,"interactions":80,"review":81,"examples":84,"atc":89,"iran":91,"usApproval":103,"links":109,"populations":125},"raloxifene",1,{"fa":7,"en":8},"رالوکسیفن","Raloxifene","genitourinary-sex-hormones",{"fa":11,"en":12},"تعدیل‌کننده انتخابی گیرنده استروژن (SERM)","Selective oestrogen receptor modulator",[14],{"name":15,"market":16},"Evista","US",[18,19,7],"evista","اویستا",[21],{"id":22,"form":23,"route":24,"label":25,"concentration":26,"markets":30,"refs":31},"tab-60","tablet","oral","60 mg tablet",{"amount":27,"unit":28,"perUnit":23,"scored":29},60,"mg",false,[16],[32],{"source":33,"section":34},"fda-raloxifene","3",[36],{"id":37,"disease":38,"label":39,"population":42,"type":46,"unit":28,"dose":47,"refs":48,"notes":51},"pmo","osteoporosis",{"fa":40,"en":41},"پوکی استخوان یائسگی (درمان یا پیشگیری) — ۶۰ mg یک بار در روز","Postmenopausal osteoporosis (treatment or prevention) — 60 mg once daily",{"minAge":43},{"value":44,"unit":45},18,"year","fixed",{"perDose":27,"dosesPerDay":5},[49],{"source":33,"section":50},"2.1",[52],{"text":53,"refs":56},{"fa":54,"en":55},"بدون توجه به غذا. کلسیم و ویتامین D در صورت دریافت ناکافی.","With or without food. Calcium and vitamin D if intake is inadequate.",[57,58],{"source":33,"section":50},{"source":33,"section":59},"2.2",[61],{"id":62,"severity":63,"text":64,"refs":67},"ci","block",{"fa":65,"en":66},"ترومبوآمبولی وریدی فعال یا قبلی (DVT، PE، ترومبوز ورید شبکیه)؛ بارداری.","Active or past VTE (DVT, PE, retinal vein thrombosis); pregnancy.",[68],{"source":33,"section":69},"4",[71],{"text":72,"refs":75},{"fa":73,"en":74},"هشدار جعبه‌ای: افزایش خطر ترومبوآمبولی وریدی و مرگ ناشی از سکته.","Boxed warning: increased risk of venous thromboembolism and death from stroke.",[76],{"source":33,"section":77},"Boxed Warning",[],[],[],{"status":82,"reviewer":83,"date":83},"unverified",null,[85],{"regimen":37,"formulation":22,"input":86,"expect":88},{"ageYears":27,"weightKg":87},65,{"perDose":27,"tabletsPerDoseRounded":5},[90],"G03XC01",{"status":92,"forms":93,"refs":98},"registered",[94],{"code":95,"en":96,"fa":97},"01926","RALOXIFENE 60MG TAB","قرص رالوکسیفن ۶۰ میلی‌گرم",[99],{"source":100,"section":101,"url":102},"darooyab-generic","G-3311\u002FRaloxifene","https:\u002F\u002Fwww.darooyab.ir\u002FG-3311\u002FRaloxifene",{"kind":104,"refs":105,"id":108},"ANDA",[106],{"source":33,"section":107},"SPL approval \u002F marketing category","ANDA078193",[110,113,117,120,123],{"kind":111,"url":112,"label":108},"fda","https:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fcder\u002Fdaf\u002Findex.cfm?event=overview.process&ApplNo=078193",{"kind":114,"url":115,"label":116},"dailymed","https:\u002F\u002Fdailymed.nlm.nih.gov\u002Fdailymed\u002FdrugInfo.cfm?setid=e6be5b1d-757d-4bab-ad6a-c421960a104d","FDA Raloxifene",{"kind":118,"url":119,"label":8},"medlineplus","https:\u002F\u002Fmedlineplus.gov\u002Fdruginfo\u002Fmeds\u002Fa698007.html",{"kind":121,"url":122,"label":90},"who-atc","https:\u002F\u002Fatcddd.fhi.no\u002Fatc_ddd_index\u002F?code=G03XC01",{"kind":124,"url":102,"label":8},"darooyab",{"pregnancy":126,"lactation":134,"pediatric":143,"geriatric":152},{"level":127,"text":128,"quote":131,"refs":132},"contraindicated",{"fa":129,"en":130},"برچسب: در بارداری منع مصرف دارد.","Label: contraindicated in pregnancy.","… nd retinal vein thrombosis [ see Warnings and Precautions ( 5.1 ) ]. 4.2 Pregnancy Raloxifene hydrochloride tablets are contraindicated for use in pregnancy, as it may cause fetal harm [ see Use in Specific Populations ( 8.1 ) ].",[133],{"source":33,"section":69},{"level":135,"text":136,"quote":139,"refs":140},"caution",{"fa":137,"en":138},"برچسب: در شیردهی با احتیاط؛ متن برچسب را ببینید.","Label: use with caution while breastfeeding; see the label text.","Risk Summary Raloxifene hydrochloride is not indicated for use in females of reproductive potential.",[141],{"source":33,"section":142},"8.2",{"level":144,"text":145,"quote":148,"refs":149},"not-established",{"fa":146,"en":147},"برچسب: ایمنی و اثربخشی در کودکان ثابت نشده است.","Label: safety and effectiveness in children have not been established.","Safety and effectiveness in pediatric patients have not been established.",[150],{"source":33,"section":151},"8.4",{"level":135,"text":153,"quote":156,"refs":157},{"fa":154,"en":155},"برچسب: در سالمندان با احتیاط و معمولاً از دوز پایین شروع شود.","Label: use with caution in older adults, usually starting at the low end of the dose range.","Of the total number of patients in placebo-controlled clinical studies of raloxifene hydrochloride, 61% were 65 and over, while 15.5% were 75 and over.",[158],{"source":33,"section":159},"8.5",1792111466782]